# Therini Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/therini-bio

- Industry: Biotechnology
- Headquarters: Sacramento, US
- Website: www.therinibio.com
- Total disclosed funding: $101M
- Latest round: Series A (May 14, 2025)
- Investors on record: 10

## About

Founded in 2016 and based in California, US, Therini Bio, Inc., formerly known as MedaRed, Inc., is a biotechnology company that offers treatments to protect the nervous system from multiple sclerosis damage. The company was founded by Katerina Akassoglou. In April 2023, Therini Bio, Inc. raised an amount of USD 36 million in Series A funding co-led by MRL Ventures Fund, Sanofi Ventures, SV Health Investors, and The Alzheimer's Drug Discovery Foundation. The series A funding values Therini Bio, Inc. at USD 88.75 million post-money. As of 2024, the company is led by its CEO, Tara Nickerson. In May 2025, Therini Bio, Inc. raised USD 39 million in series A funding led by new investor Angelini Ventures, with participation from another new investor Apollo Health Ventures. Returning investors Dementia Discovery Fund, Dolby Family Ventures, Eli Lilly & Company, Foundation for a Better World, MRL Ventures Fund, Sanofi Ventures, and SV Health Investors also participated in the round. Therini Bio develops novel therapies, mainly fibrin-targeted therapies and immunotherapies for neurological and inflammatory diseases such as Alzheimer’s disease (AD) and multiple sclerosis (MS). The firm’s pipeline product line includes THN391, systemic, a drug candidate for Alzheimer’s disease; THN39, IVT, a drug candidate for diabetic macular edema (DME); and bispecific fibrin/VEGF, a drug candidate for diabetic macular edema (DME). The company's research targets and attaches antibodies to fibrin without affecting critical clotting functions. The company plans to utilize the May 2025 funding to conduct early-stage clinical trials of its lead therapy for Alzheimer's disease and diabetic eye disease and to develop a dual-target treatment that addresses vascular and inflammatory factors.

## Funding rounds

- Series A, May 14, 2025, $39M — SV Health Investors, Sanofi Ventures, Eli Lilly & Company, Dolby Family Ventures, Apollo Health Ventures, MRL Ventures Fund, Foundation for a Better World, Angelini Ventures
- Series A, Apr 27, 2023, $36M — SV Health Investors, Sanofi Ventures, Dolby Family Ventures, Alzheimer's Drug Discovery Foundation, MRL Ventures Fund, Lilly, Foundation for a Better World
- Seed, May 10, 2021, $17M — SV Health Investors, Sanofi Ventures, Dolby Family Ventures, MRL Ventures Fund, Foundation for a Better World
- Seed, May 15, 2020, $7M — SV Health Investors, Alzheimer's Drug Discovery Foundation
- Seed, May 8, 2019, $2.4M — SV Health Investors, Dolby Family Ventures

## Investors

- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Seed, Series A
- Dolby Family Ventures (https://capitalatlas.ai/funds/dolby-family-ventures) — Seed, Series A
- Alzheimer's Drug Discovery Foundation — Seed, Series A
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Seed, Series A
- MRL Ventures Fund (https://capitalatlas.ai/funds/mrl-ventures-fund) — Seed, Series A
- Foundation for a Better World — Seed, Series A
- Lilly — Series A
- Eli Lilly & Company — Series A
- Apollo Health Ventures (https://capitalatlas.ai/funds/apollo-health-ventures) — Series A
- Angelini Ventures (https://capitalatlas.ai/funds/angelini-ventures) — Series A